FOCAL OSTEOMALACIA DUE TO LOW-DOSE DIPHOSPHONATE THERAPY IN PAGET'S DISEASE
- 1 April 1984
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 323 (8381) , 821-824
- https://doi.org/10.1016/s0140-6736(84)92272-4
Abstract
No abstract availableThis publication has 19 references indexed in Scilit:
- Review of Fracture Experience During Treatment of Paget??s Disease of Bone with Etidronate Disodium (EHDP)Published by Wolters Kluwer Health ,1983
- DIPHOSPHONATES AND INHIBITION OF BONE MINERALISATIONThe Lancet, 1982
- DIPHOSPHONATES AND INHIBITION OF BONE MINERALISATIONThe Lancet, 1982
- Effects of ethane-1 hydroxy-1, 1-Diphosphonate (5 mg/kg/day dose) onquantitative bone histology in paget's disease of boneMetabolic Bone Disease and Related Research, 1981
- A LOW DOSE REGIME OF 1α HYDROXYVITAMIN D3IN THE MANAGEMENT OF SENILE OSTEOPOROSIS: A PILOT STUDYClinical Endocrinology, 1980
- Age- and sex-related reference ranges for eight plasma constituents derived from randomly selected adults in a Scottish new town.Journal of Clinical Pathology, 1980
- Frequency distribution and 'reference values' of plasma alkaline phosphatase (EC 3.1.3.1) activity in the adult population of a Scottish new town.Journal of Clinical Pathology, 1978
- DIPHOSPHONATES IN PAGET'S DISEASEThe Lancet, 1974
- Diphosphonate Treatment of Paget's Disease of BoneHormone and Metabolic Research, 1974
- Tetracycline-based histological analysis of bone remodelingCalcified Tissue International, 1969